Article ID Journal Published Year Pages File Type
3364682 International Journal of Infectious Diseases 2009 7 Pages PDF
Abstract

SummaryBackgroundTreatment rates for hepatitis C virus (HCV) have not been compared directly between HCV mono-infected and HCV–HIV co-infected patients in academic center settings.MethodsWe prospectively enrolled consecutive mono-infected and co-infected subjects at three academic centers in the USA. Clinical and laboratory data were gathered through interviews and medical records. Logistic regression analysis was used to determine the factors associated with treatment prescription for HCV.ResultsThe 241 HCV mono-infected and 158 HCV–HIV co-infected subjects were similar in age, but there were more blacks (58.9% vs. 30.7%, p < 0.001) and males (81.6% vs. 58.5%, p < 0.001) in the latter group. The co-infected subjects were less likely to have a liver biopsy (43.7% vs. 71.4%, p < 0.001) or ever receive treatment for HCV (32.3% vs. 62.2%, p < 0.001). In bivariate analysis, subjects not prescribed treatment for HCV were more likely to be black, have HIV co-infection, and have ongoing alcohol abuse. In multivariate analysis, black race (odds ratio (OR) 0.44, 95% confidence interval (CI) 0.28–0.70) and HIV co-infection (OR 0.33, 95% CI 0.21–0.53) were independently associated with non-prescription of treatment.ConclusionsBlack race and HIV co-infection are associated with a lower likelihood of treatment for HCV. Addressing comorbidities in these populations may help to reduce such treatment disparities.

Related Topics
Life Sciences Immunology and Microbiology Applied Microbiology and Biotechnology
Authors
, , , , , , , ,